Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer
A phase 3 trial of Camrelizumab in cervical cancer, run by Jiangsu HengRui Medicine Co., Ltd., active and no longer recruiting.
Overview
Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer is a phase 3 interventional study registered as NCT04906993 by Jiangsu HengRui Medicine Co., Ltd., with 443 participants enrolled, started 2021-07-23 and due to reach its primary completion in 2025-06-10. Interventions recorded: camrelizumab； famitinib malate and platinum-based chemotherapy.
Similar pages
not linked directly; found by shared links- TrialStudy to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC
Shares Camrelizumab, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialA Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer
Shares Cervical cancer and the tag pipeline.
- TrialA Phase II Clinical Trial of SHR-1826 for Non-Small Cell Lung Cancer
Shares Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialA TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS
Shares Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialHetrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Solid Tumors.
Shares Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialAn Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.
Shares Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialA Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors
Shares Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialA Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors
Shares Jiangsu Hengrui Pharmaceuticals and the tag pipeline.